Sodium channels as molecular targets for antiepileptic drugs

被引:183
作者
Ragsdale, DS
Avoli, M
机构
[1] McGill Univ, Montreal Neurol Inst, Cell Biol Excitable Tissues Grp, Montreal, PQ H3A 2B4, Canada
[2] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada
[3] McGill Univ, Dept Physiol, Montreal, PQ H3A 2B4, Canada
关键词
sodium channel; antiepileptic drug; phenytoin; carbamazepine; valproate; lamotrigine; topiramate;
D O I
10.1016/S0165-0173(97)00054-4
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Voltage-gated sodium channels mediate regenerative inward currents that are responsible for the initial depolarization of action potentials in brain neurons. Many of the most widely used antiepileptic drugs, as well as a number of promising new compounds suppress the abnormal neuronal excitability associated with seizures by means of complex voltage-and frequency-dependent inhibition of ionic currents through sodium channels. Over the past decade, advances in molecular biology have led to important new insights into the molecular structure of the sodium channel and have shed light on the relationship between channel structure and channel function. In this review, we examine how our current knowledge of sodium channel structure-function relationships contributes to our understanding of the action of anticonvulsant sodium channel blockers. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:16 / 28
页数:13
相关论文
共 114 条
[91]   INTERACTIONS OF THE ANTI-CONVULSANT CARBAMAZEPINE WITH ADENOSINE RECEPTORS .1. NEUROCHEMICAL STUDIES [J].
SKERRITT, JH ;
DAVIES, LP ;
JOHNSTON, GAR .
EPILEPSIA, 1983, 24 (05) :634-642
[92]   INHIBITION OF SODIUM CURRENTS IN MYELINATED NERVE BY QUATERNARY DERIVATIVES OF LIDOCAINE [J].
STRICHARTZ, GR .
JOURNAL OF GENERAL PHYSIOLOGY, 1973, 62 (01) :37-57
[93]   STRUCTURAL PARTS INVOLVED IN ACTIVATION AND INACTIVATION OF THE SODIUM-CHANNEL [J].
STUHMER, W ;
CONTI, F ;
SUZUKI, H ;
WANG, XD ;
NODA, M ;
YAHAGI, N ;
KUBO, H ;
NUMA, S .
NATURE, 1989, 339 (6226) :597-603
[94]   Role of an S4-S5 linker in sodium channel inactivation probed by mutagenesis and a peptide blocker [J].
Tang, LH ;
Kallen, RG ;
Horn, R .
JOURNAL OF GENERAL PHYSIOLOGY, 1996, 108 (02) :89-104
[95]   Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy [J].
Tassinari, CA ;
Michelucci, R ;
Chauvel, P ;
Chodkiewicz, J ;
Shorvon, S ;
Henriksen, O ;
Dam, M ;
Reife, R ;
Pledger, G ;
Karim, R .
EPILEPSIA, 1996, 37 (08) :763-768
[96]  
Taylor C P, 1997, Adv Pharmacol, V39, P47, DOI 10.1016/S1054-3589(08)60069-1
[97]   LAMOTRIGINE AS AN ADD-ON DRUG IN THE MANAGEMENT OF LENNOX-GASTAUT SYNDROME [J].
TIMMINGS, PL ;
RICHENS, A .
EUROPEAN NEUROLOGY, 1992, 32 (06) :305-307
[98]  
TOMAN JEP, 1949, ELECTROEN CLIN NEURO, V1, P33, DOI 10.1016/0013-4694(49)90008-5
[99]   MU-I NA+ CHANNELS EXPRESSED TRANSIENTLY IN HUMAN EMBRYONIC KIDNEY-CELLS - BIOCHEMICAL AND BIOPHYSICAL PROPERTIES [J].
UKOMADU, C ;
ZHOU, JY ;
SIGWORTH, FJ ;
AGNEW, WS .
NEURON, 1992, 8 (04) :663-676
[100]   IDENTIFICATION OF AN INTRACELLULAR PEPTIDE SEGMENT INVOLVED IN SODIUM-CHANNEL INACTIVATION [J].
VASSILEV, PM ;
SCHEUER, T ;
CATTERALL, WA .
SCIENCE, 1988, 241 (4873) :1658-1661